-
New Findings on Blinatumomab for Childhood B-Cell Acute Lymphoblastic Leukemia (B-Cell ALL)!
On December 7, 2024, a phase 3 trial published in The New England Journal of Medicine provided compelling evidence on the addition of blinatumomab to chemotherapy in children with newly…
-
News of ASH：Application of the Ketogenic Diet in CAR-T Therapy
The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the latest developments, Hematology Frontier presents the News of ASH series, offering key takeaways…
-
Unlocking the Prognostic Power of ctDNA in Colorectal Cancer: Insights from a Landmark Study
The CALGB/SWOG 80702 trial enrolled 2,526 patients with resected adenocarcinoma of the colon without metastatic disease. Of these, 1,752 patients consented to biospecimen collection, leading to the successful banking of…
-
News of ASH：Gut Microbiota and CAR-T Therapy
The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided valuable insights into fundamental research, innovative therapies, and disease management in hematology. To distill the essence of ASH and capture the latest advancements in the field, Hematology Frontier…
-
News of ASH：Overview of Acute Myeloid Leukemia Research Advances in 2024
The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, gathering over 30,000 experts and scholars from around the world. This year’s conference featured numerous carefully curated sessions, providing profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the key findings from ASH 2024, Hematology Frontier presents the…
-
Revolutionizing Treatment for MSI-H/dMMR Metastatic Colorectal Cancer: The Promising Results of the CheckMate 8HW Trial
Patient Characteristics The trial included 1,059 patients randomized into three treatment arms: nivolumab monotherapy, nivolumab plus ipilimumab, and investigator’s choice chemotherapy (mFOLFOX6 or FOLFIRI with or without bevacizumab or cetuximab).…
-
ASCO GU 2025 | Dr. Xuefeng Qiu and Dr. Darren Poon：Advancing Precision Medicine in Prostate Cancer
The 2025 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2025) has already taken place in San Francisco, USA. This globally renowned academic event brought together top oncology scholars to jointly explore the cutting-edge breakthroughs and future directions in the field of genitourinary oncology.In this insightful exchange, Dr. Xuefeng Qiu from…
-
ASCO GU 2025 | Professors Jun Guo, Xinan Sheng, and Bixia Tang: Chinese Innovative Drugs Enter the Global Stage, Expanding the Benefits in Urothelial
With the rapid advancement of ADC-based combination immunotherapies globally, the treatment landscape for advanced urothelial carcinoma has undergone a dramatic transformation, leading to multiple updates in clinical guidelines. This year’s ASCO Genitourinary Cancers Symposium (ASCO GU) was held from February 13–15 in San Francisco, where Professor Jun Guo from Peking University Cancer Hospital led a…
Connecting Medical Expertise through Media